Key Highlights
- Ottobock will absorb Fesia Technology’s FES orthoses, expanding its neuro‑orthotics range before the transaction closes in the next six months.
- The acquisition gives Ottobock entry to a platform that treats stroke, multiple sclerosis and cerebral palsy with wearable electrical stimulation.
- GlobalData projects the worldwide neurology‑devices market to top $25bn by 2034, while WHO data show the burden of neurological disorders has risen 18% since 1990.
Ottobock announced it will acquire Spanish medical‑device specialist Fesia Technology, adding functional electrical stimulation (FES) solutions to its neuro‑orthotics portfolio. The transaction, whose financial terms remain undisclosed, is expected to be completed within the next six months.
Deal Terms
Under the agreement, Ottobock will take over Fesia’s product portfolio, which comprises the foot‑drop correction system known as Fesia Walk and the hand‑therapy device called Fesia Grasp. The existing owners, a group of private investors, will exit their positions as part of the transaction.
Strategic Rationale
Ottobock’s leadership points to a growing global prevalence of neurological conditions and expanding applications of functional electrical stimulation, such as spinal‑cord injury rehabilitation. By integrating Fesia’s wearable orthoses, which deliver calibrated electrical pulses to weakened muscles, Ottobock strengthens its position in a neurology‑devices market projected to surpass $25bn. The acquisition also aligns with WHO data that the health burden from neurological disorders has risen 18% since 1990, especially in low‑ and middle‑income regions.
The broader market context shows heightened interest from healthcare systems seeking cost‑effective, home‑based rehabilitation technologies. Advances in sensor integration and data analytics are enabling more personalized therapy regimes, driving demand for devices that combine comfort with therapeutic efficacy.
What’s Next
Following closure, Ottobock plans to scale Fesia’s technology worldwide, leveraging its existing distribution network and regulatory expertise. The combined portfolio will be managed through a unified platform that uses the Fesia Pro smartphone app to personalize stimulation parameters for each patient. Executives expect the broadened offering to accelerate growth in the neuro‑orthotics segment as demand for advanced rehabilitation solutions continues to climb.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_18_51_41_746812.jpg)


Please wait processing your request...